Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 01 2024 - 8:00AM
Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company
aspiring to address the unmet medical needs of patients with cancer
through paradigm-shifting therapeutics, will host a virtual
investor event reviewing preliminary clinical data from its Phase 1
dose-escalation study of VIP236 and provide an update on pipeline
progress on Monday, April 8, 2024, at 2 PM PT. This will follow the
poster presentation of the VIP236 clinical data at the AACR Annual
Meeting 2024.
The virtual investor event will include presentations
by Ahmed Hamdy, MD, CEO of Vincerx Pharma, along with key
opinion leaders, Uma Borate, MD, MBBS, Clinical Associate Professor
in the Division of Hematology at The Ohio State University
Comprehensive Cancer Center - Arthur G. James Cancer Hospital and
Richard J. Solove Research Institute, and Vivek Subbiah, MD, Chief
of Early-Phase Drug Development at Sarah Cannon Research
Institute.
To register and view the live webcast, please visit:
https://edge.media-server.com/mmc/p/xhv7kxf7/. An archived replay
of the webcast will be available on the Vincerx Investor Page
website following the conclusion of the live event.
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical
company committed to developing differentiated and novel therapies
to address the unmet medical needs of patients with cancer. Vincerx
has assembled a seasoned management team with a proven track record
of successful oncology drug development, approvals, and value
creation. Vincerx’s diverse pipeline consists of the
next-generation antibody-drug conjugate, VIP943, in Phase 1; small
molecule-drug conjugate, VIP236, in Phase 1; preclinical
antibody-drug conjugate, VIP924; CDK9 inhibitor, enitociclib, in
an NIH-sponsored Phase 1; and VersAptx™, its versatile and
adaptable, next-generation bioconjugation platform.
Vincerx is based in Palo Alto, California, and has a
research facility in Monheim, Germany. For more information,
please visit www.vincerx.com and follow Vincerx
on LinkedIn.
Vincerx, the Vincerx logo, and VersAptx are Vincerx
trademarks.
Contacts
Gabriela JairalaVincerx Pharma,
Inc.gabriela.jairala@vincerx.com
Totyana SimienInizio Evoke
Commstotyana.simien@inizioevoke.com
Vincerx (NASDAQ:VINC)
Historical Stock Chart
From Apr 2024 to May 2024
Vincerx (NASDAQ:VINC)
Historical Stock Chart
From May 2023 to May 2024